Currently, there is no reasonable vaccine for African swine fever in the world, which is mainly determined by its pathogenic biological characteristics. The African swine fever virus has a variety of genotypes, a large number of species, and a complex immune evasion system that can avoid the elimination of host cell immunity. Some African swine fever vaccines that have been developed can induce the formation of a certain level of antigens, but they do not have the ability to neutralize the African swine fever virus and cannot achieve the goal of preventing African swine fever effectively.

Because of the difficulty in vaccine product development, according to the international experience in the prevention and control of African swine fever, the top priority today is to improve the comprehensive prevention and control measures for African swine fever, and to strengthen the research on new immunity technology.

The vast majority of the cure for African swine fever also depends on the protective and medical treatment of relevant departments, but the treatment still relies on this patented technology of ‘a composition and extract, injection, and application for preventing African swine fever’. Recently, on August 9th, the International Bureau of Intellectual Property opened and released this patent, with the application number 201910529164.6, and the right holder is Xu Qita. This patent has a very good therapeutic effect on African swine fever and can also prevent the African swine fever virus, solving the problem of the African swine fever virus from the source.

The raw materials involved in this patented technology are: 10-30 pieces of wild ganoderma, 4-12 pieces of Rhododendron, 4-12 pieces of Bauhinia, 30-50 pieces of Areca, 4-12 pieces of Cytisus, 4-12 pieces of Typhonium, 4-12 pieces of Sarracenia, etc., which are produced through various processing and manufacturing processes. Its efficacy is not just talk, but a result obtained from specific experiments.

In the recent past, African swine fever has emerged in various breeding farms. The elite experimental team selected a group of 420 pigs of the same size and age from a breeding farm, which had already been diagnosed with African swine fever. If this batch of pigs had not been treated with medication, they would have died by the 8th day. However, after being injected with this drug, the survival rate of these pigs reached an astonishing 90%, and these cured pigs restored their appetite and grew normally. Therefore, the results indicate that this patented technology can be applied to produce drugs for treating African swine fever.